Description
DOTA-LM3 TFA is a synthetic peptide designed as a somatostatin receptor (SSTR) antagonist. The LM3 sequence refers to p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH?. This peptide is often isotopically labeled for in vivo tumor tracing, such as with 177Lu-DOTA-LM3 TFA and 68Ga-DOTA-LM3 TFA.
177Lu-DOTA-LM3 TFA is utilized in research on DOTATOC-negative liver metastases, including pancreatic neuroendocrine tumors (NETs) and extensive tumor thrombosis.
68Ga-DOTA-LM3 TFA exhibits favorable biodistribution, high tumor uptake, good tumor retention, and minimal safety concerns.
DOTA-LM3 TFA is also employed in the synthesis and research of Radionuclide-Drug Conjugates (RDCs), offering potential in targeted cancer therapies.
Manufactured under GMP standards with a purity of 99.30%, DOTA-LM3 TFA ensures consistency and reliability for experimental use.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | DOTA-LM3 TFA |
| Synonyms | LM3 TFA, p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH? |
| CAS No. | 1192362-32-5 |
| Purity | 99.30% (GMP-grade) |
| Molecular Formula | C??H??ClF?N??O??S? |
| Molecular Weight | 1664.18 g/mol |
| Appearance | White to off-white powder |
| Solubility | Soluble in water and DMSO |
| Storage Conditions | Store at –20?°C, protect from light and moisture |
| Applications | Tumor tracing, Radionuclide-Drug Conjugate research |
| Regulatory Status | For laboratory research use only |
Mechanism of Action & Research Applications
Mechanism of Action:
DOTA-LM3 TFA functions as a somatostatin receptor (SSTR) antagonist. The LM3 peptide sequence is designed to bind to SSTRs, inhibiting their activity and providing a means to trace tumors in vivo when isotopically labeled.
Research Applications:
Tumor Tracing: Utilizing isotopically labeled DOTA-LM3 TFA (e.g., 177Lu-DOTA-LM3 TFA, 68Ga-DOTA-LM3 TFA) for imaging and locating tumors.
Radionuclide-Drug Conjugates (RDCs): Employing DOTA-LM3 TFA in the development of targeted therapies combining radionuclides and drugs.

Side Effects (Research Context Only)
DOTA-LM3 TFA is intended for laboratory research use only. In preclinical studies, it has been shown to exhibit favorable biodistribution and tumor uptake with minimal safety concerns. However, as with all experimental compounds, appropriate safety protocols should be followed during handling and administration.
Disclaimer
DOTA-LM3 TFA is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Users should adhere to institutional safety guidelines and regulatory requirements when handling this compound.



Reviews
There are no reviews yet.